Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1H-Pyrrol-3-yl)-2-oxazolidinones
摘要:
Monoamine oxidases (MAOs) are involved in various psychiatric and neurodegenerative disorders; hence, MAO inhibitors are useful agents in the therapy of Parkinson's disease, Alzheimer's dementia, and depression syndrome. Herein we report a novel series of 3-(1H-pyrrol-3-yl)-2-oxazolidinones 3-7 as reversible, highly potent and selective anti-MAO-A agents. In particular, 4b, 5b, and 4c showed a Ki-MAO-A of 0.6, 0.8, and I nM, respectively, 4c being 200000-fold selective for MAO-A with respect to MAO-B.
Synthetically useful [1,2-a]-fused pyrroles, e.g. 2,3-dihydro-1H-pyrrolizidines substituted in the 1- and 7-positions, have been generated by acyl radical cyclisation onto pyrroles using N-(omega -acyl)-radicals generated front acyl-selenide precursors. The protocol does not require high pressures of CO. Mechanistic studies indicate the key role of azo radical initiators as oxidants of the intermediate pi -radicals. (C) 2001 Elsevier Science Ltd. All rights reserved.
作者:Steven M. Allin、William R.S. Barton、W. Russell Bowman、Emma Bridge (née Mann)、Mark R.J. Elsegood、Tom McInally、Vickie McKee
DOI:10.1016/j.tet.2008.06.014
日期:2008.8
Alkyl radicals have been cyclised onto pyrroles, imidazoles and pyrazoles, and acyl radicals cyclised onto pyrroles, using Bu3SnH-, (TMS)3SiH- and Bu3GeH-mediated aromatic homolytic substitution for the synthesis of bicyclic N-heterocycles. The reactions yield intermediate π-radicals that lose hydrogen in the rearomatisation step of the aromatic homolytic substitution. Mechanistic studies of these
[EN] 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS<br/>[FR] INHIBITEURS DE LA 17?-HYDROXYLASE/C17,20-LYASE
申请人:NOVARTIS AG
公开号:WO2012035078A1
公开(公告)日:2012-03-22
The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.